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Abstract
A series of Pt(IV) prodrugs has been obtained by oxidative halogenation of either cisplatin or 
carboplatin. Iodobenzene dichloride is a general reagent that cleanly provides prodrugs bearing 
axial chlorides without the need to prepare intervening Pt(IV) intermediates or handle chlorine 
gas. Elemental bromine and iodine afford Pt(IV) compounds as well, although in the case of the 
iodine-mediated oxidation of carboplatin, an amido-bridged Pt(IV) side product also formed. A 
detailed analysis of the changes in spectroscopic and structural parameters induced by varying the 
axial halide is presented. A number of recurring motifs are observed in the solid state structures of 
these compounds.
Introduction
Platinum complexes play a significant role in the clinical treatment of cancer, with cisplatin, 
carboplatin, and oxaliplatin (Chart 1) comprising one of the most widely prescribed classes 
of antineoplastic drugs.1 These three coordination complexes feature platinum in the 2+ 
oxidation state. Indeed, this oxidation state, and the square-planar coordination geometry 
that platinum(II) almost invariably adopts, long dominated the landscape of platinum drug 
development. Despite the monopoly that Pt(II) holds over the market for platinum-based 
drugs, platinum(IV) complexes also have biological activity, as revealed in some of the 
earliest experiments.2 Pt(IV) compounds were extensively pursued in preclinical and clinical 
settings early in the history of this class of drugs (Chart 1).3 The status of satraplatin (Chart 
1) was closely monitored as it progressed through clinical trials, although it ultimately failed 
to achieve the desired increased lifespan when used in combination with prednisone for 
treatment of hormone-refractory prostate cancer.4
Pt(IV) compounds as a class act as prodrugs that undergo intracellular reduction to yield 
active Pt(II) species, which can proceed to bind nuclear DNA and initiate a cellular response 
that eventually triggers cell death pathways.5 Pt(IV) prodrugs typically contain the four 
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ligands of a Pt(II) precursor of known anticancer activity arranged in a square-planar 
geometry with two additional ligands, disposed trans to one another, completing the 
octahedral coordination sphere.6 Although it is widely stated that reduction of Pt(IV) 
prodrugs proceeds with loss of these two additional, so-called “axial” ligands, recent studies 
reveal that other reduction products are possible.7,8 The nature of the ligands bound to the 
Pt(IV) center significantly influences the mechanism and kinetics of reduction.9,10
Most Pt(IV) prodrugs bear axial chloride, hydroxide, or carboxylate ligands because of the 
synthetic ease with which they can be installed.11 Oxidation of a Pt(II) complex with 
hydrogen peroxide in water typically affords the Pt(IV) derivative with two trans hydroxide 
ligands in which the relative geometry of the ligands bound originally to the metal center 
remains undisturbed. The metal-bound hydroxide ligands are sufficiently nucleophilic to 
attack carboxylic acid anhydrides to yield Pt(IV) carboxylates.11 Similar nucleophilic attack 
of other substrates can afford Pt(IV) carbonates and carbamates.12,13 Treatment with 
hydrochloric acid results in substitution of the hydroxide ligands for chloride, presumably 
through an intermediate bearing aqua ligands.14 Pt(IV) prodrugs with chloride axial ligands 
can also be obtained by direct oxidation with chlorine gas.15
In the course of exploring the chemistry of Pt(IV) prodrugs, the oxidative halogenation of 
cisplatin and carboplatin was investigated with the aim of expanding the range of commonly 
encountered axial ligands and the synthetic methodologies for accessing them (Chart 2). We 
found iodobenzene dichloride to be a suitable replacement for chlorine gas in the preparation 
of prodrugs with axial chloride ligands. Bromine and iodine are more suitable than chlorine 
for laboratory handling and provided ready access to prodrugs having axial bromide and 
iodide ligands, respectively. An unexpected dimerization occurred as a side reaction upon 
treatment of carboplatin with I2. Here we report details of the synthesis and characterization 
of these compounds and anticipate that these reactions will be readily applicable to the 
preparation of Pt(IV) prodrugs from other biologically active Pt(II) complexes. The crystal 
structures of several of these prodrugs, as well as those of related platinum complexes, were 
determined, salient features of which are discussed.
Experimental
General considerations
Unless otherwise specified, reactions were conducted in a fume hood with protection from 
light. Reactions leading to the formation of the Pt(IV) iodide complexes were particularly 
prone to photodecomposition. All reagents were used as received from commercial vendors 
without further purification. Carboplatin was prepared as previously described.16 cis,trans-
[Pt(CBDCA)(NH3)2(OH)2], where CBDCA is 1,1-cyclobutane-dicarboxylate, was prepared 
as previously reported.17
Physical Measurements
1H, 13C, 14N, or 195Pt NMR spectra were acquired on either a Varian Inova-500 or a Bruker 
DPX-400 spectrometer in the MIT Department of Chemistry Instrumentation Facility 
(DCIF) at room temperature. Resonant absorptions are reported as chemical shifts (δ) in 
ppm with respect to tetramethylsilane (1H and 13C), NH4Cl (14N), or Na2PtCl6 (195Pt). 
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NMR spectra were referenced to residual solvent signals (1H and 13C), an external solution 
of NH4Cl in 0.1 M HCl (14N δ = 0 ppm), or an external solution of K2PtCl4 in D2O (195Pt δ 
= −1628 ppm). 14N NMR spectra were acquired for 1 and 2 but not 3–6.18 Elemental 
analyses for the previously unreported compounds 4–6 were provided by a commercial 
laboratory. Combustion analyses were not carried out for the known compounds 1–3.
Synthesis of iodobenzene dichloride
The synthesis is a modification of that previously reported.19 Iodobenzene (250 mg, 1.22 
mmol) was suspended in household bleach (10 mL, 5.25% NaClO). Concentrated 
hydrochloric acid was added in a dropwise manner until gas evolution ceased (ca. 2 mL). 
The resulting yellow precipitate was collected by filtration, washed with water (3 × 10 mL), 
air dried, and washed with hexanes (3 × 10 mL). The solid was dissolved in a minimal 
amount of hot chloroform and cooled to room temperature. The solution was allowed to 
stand at −40 °C overnight. Yellow needles formed and were collected by filtration, washed 
with hexanes, and dried in vacuo for 2 h. Yield 240 mg, 72%. Spectroscopic characterization 
matches that previously reported.19
Synthesis of cis-[Pt(NH3)2Cl4] (1)
Cisplatin (100 mg, 0.33 mmol) was suspended in DMF (2 mL). A solution of iodobenzene 
dichloride (92 mg, 0.33 mmol) in DMF (1 mL) was added to the cisplatin suspension. The 
color of the suspension briefly turned deep orange, but quickly lightened to a bright yellow 
and all of the solids dissolved. The mixture was stirred at room temperature for 10 min 
followed by addition of diethyl ether (30 mL) to precipitate a yellow solid. The solid was 
collected by filtration, washed with diethyl ether, and dried in vacuo. Yield: 121 mg, 99%. 
M.p. 220–230 °C (dec). 1H NMR (500 MHz, DMF-d7) δ 5.87 (1JH–N = 55 Hz, 2JH–Pt = 50 
Hz). 1H NMR (400 MHz, DMSO-d6) δ 5.83 (1JH–N = 52 Hz, 2JH–Pt = 56 Hz). 14N NMR 
(28.9 MHz, DMSO-d6) δ –33.7 (1JN–H = 53 Hz, 1JN–Pt = 177 Hz). 195Pt NMR (108 MHz, 
DMF-d7) δ –257. 195Pt NMR (86 MHz, DMSO-d6) δ –127.
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2Br2] (2)
Cisplatin (100 mg, 0.33 mmol) was suspended in DMF (2 mL). A solution of bromine (53 
mg, 0.33 mmol) in DMF (1 mL) was added to the cisplatin suspension. The mixture was 
stirred at room temperature for 10 min. Addition of diethyl ether (15 mL) resulted in 
precipitation of an orange solid. The solid was collected by filtration, washed with diethyl 
ether, and dried in vacuo. Yield: 121 mg, 80%. M.p. 200–220 °C (dec). 1H NMR (400 MHz, 
DMSO-d6) δ 5.77 (1JH–N = 52 Hz, 2JH–Pt = 52 Hz). 14N{1H} NMR (28.9 MHz, DMSO-d6) 
δ −40.9 (1JN–Pt = 175 Hz). 195Pt NMR (86 MHz, DMSO-d6) δ −732 (1JPt–N = 175 
Hz, 2JPt–H = 50 Hz).
Synthesis of cis,cis,trans-[Pt(NH3)2Cl2I2] (3)
Cisplatin (100 mg, 0.33 mmol) was suspended in DMF (2 mL). A solution of iodine (84 mg, 
0.33 mmol) in DMF (2 mL) was added to the cisplatin suspension. The mixture was stirred 
at room temperature for 10 min. Addition of diethyl ether (25 mL) resulted in precipitation 
of a red-purple solid. The solid was collected by filtration, washed with diethyl ether, and 
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dried in vacuo. Yield: 133 mg, 73%. M.p. 205–218 °C (dec). 1H NMR (500 MHz, DMF-d7) 
δ 5.77 (1JH–N = 53 Hz). 195Pt NMR (108 MHz, DMF-d7) δ −1866.
Synthesis of cis,trans-[Pt(CBDCA)(NH3)2Cl2] (4)
Carboplatin (100 mg, 0.27 mmol) was suspended in DMF (6 mL). A solution of 
iodobenzene dichloride (83 mg, 0.30 mmol) in DMF (2 mL) was added to the carboplatin 
suspension. The mixture was stirred at 75 °C for 30 min after which time the solid was 
consumed producing a yellow solution. The solution was concentrated under vacuum to a 
volume of approximately 5 mL. Methanol (1 mL) was added and the solution was filtered 
through Celite. Addition of diethyl ether (15 mL) resulted in precipitation of a yellow solid. 
The solid was collected by filtration, washed with diethyl ether, and dried in vacuo. Yield: 
97 mg, 85%. M.p. 167–173 (dec). 1H NMR (500 MHz, DMF-d7) δ 6.10 (6H, m, 1JH–N = 50 
Hz, 2JH–Pt = 45 Hz), 2.59 (4H, t, 3JH–H = 8 Hz), 1.88 (2H, p, 3JH–H = 8 Hz). 13C NMR (125 
MHz, DMSO-d6) δ 176.5, 55.8, 31.8, 15.6. 195Pt NMR (108 MHz, DMF-d7) δ 761. Anal. 
calcd for C12H26Cl2N4O6Pt: C 24.50, H 4.45, N 9.52; found: C 24.07, H 4.13, N 9.66.
Synthesis of cis,trans-[Pt(CBDCA)(NH3)2Br2] (5)
Carboplatin (150 mg, 0.40 mmol) was suspended in DMF (2 mL) and a solution of bromine 
(65 mg, 0.40 mmol) in DMF (1 mL) was added. The mixture was stirred at room 
temperature for 30 min and then at 50 °C for an additional 10 min, after which time the solid 
was consumed producing an orange solution. The mixture was filtered through Celite and 
addition of the filtrate to diethyl ether (150 mL) resulted in precipitation of an orange solid. 
The solid was collected by filtration, washed with diethyl ether, and dried in vacuo. Yield: 
181 mg, 84%. M.p. 169–172 °C (dec). 1H NMR (500 MHz, DMF-d7) δ 6.01 (6H, m, 1JH–N 
= 52 Hz, 2JH–Pt = 45 Hz), 2.60 (4H, t, 3JH–H = 10 Hz), 1.89 (2H, p, 3JH–H = 10 Hz). 13C 
NMR (125 MHz, DMSO-d6) δ 176.6, 56.0, 31.8, 15.5. 195Pt NMR (108 MHz, DMF-d7) δ 
229 (1JPt–N = 150 Hz). Anal. calcd for C6H12Br2N2O4Pt·0.3DMF (supported by NMR 
integration): C 14.99, H 2.57, N 5.83; found: C 15.32, H 2.49, N 5.33.
Oxidation of carboplatin with I2
Carboplatin (100 mg, 0.27 mmol) was suspended in DMF (2 mL). A solution of iodine (70 
mg, 0.27 mmol) in DMF (3 mL) was added to the carboplatin suspension. The mixture was 
stirred at room temperature for 30 min, during which time a yellow solid began to form. 
Addition of diethyl ether (5 mL) induced precipitation of more yellow solid and the mixture 
was cooled at 4 °C for 1 h. The yellow solid was collected by filtration and washed with 
cold DMF (8 mL) and diethyl ether (15 mL). Spectroscopic and crystallographic analysis 
revealed this substance to be the amido-bridged dimer [Pt(CBDCA)I(NH3)(μ-NH2)]2 (7). 
The red-purple filtrate was added to 100 mL of rapidly stirring diethyl ether to precipitate a 
red-brown solid. The solid was collected by filtration, washed with diethyl ether, and dried 
under vacuum. The spectroscopic properties of this complex are consistent with its 
formulation as 6. Yield: 108 mg, 64%. M.p. 164–180 °C (dec). 1H NMR (500 MHz, DMF-
d7) δ 6.25 (6H, m, 1JH–N = 52 Hz, 2JH–Pt = 50 Hz), 2.67 (4H, t, 3JH–H = 7.5 Hz), 1.90 (2H, 
p, 3JH–H = 7.5 Hz). 13C NMR (125 MHz, DMF-d7) δ 178.3, 58.1, 33.1, 16.6. 195Pt NMR 
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(108 MHz, DMF-d7) δ –856. Anal. calcd for C12H26I2N4O6Pt: C 18.69, H 3.40, N 7.26; 
found: C 18.75, H 3.18, N 7.20.
X-ray crystallography
Crystals of 1, 3, 4, and 5 were obtained by allowing diethyl ether vapor to diffuse into a 
DMF solution of the compound. The DMF-diethyl ether solvate of 1 was obtained in a 
similar manner, whereas the DMSO solvate of 1 was obtained by layering toluene onto a 
DMSO solution of the compound. Crystallization vials containing spectroscopically pure 1 
and 3 were left to stand at room temperature for more than two months and afforded crystals 
of the decomposition products fac-[Pt(NH3)3Cl3]Cl and fac-[Pt(NH3)3Br3]Br. Crystals of 7 
were obtained directly from the reaction mixture and those of cis,trans-[Pt(CBDCA)
(NH3)2(OH)2] were formed by recrystallization from hot water. Samples suitable for X-ray 
diffraction were selected microscopically under crossed polarizers, mounted on a nylon loop 
in Paratone oil, and cooled to 100 K under a stream of nitrogen. Diffraction was carried out 
on a Bruker APEX CCD X-ray diffractometer controlled by the APEX2 software using Mo 
Kα radiation (λ = 0.71073 Å).20 The data were integrated with SAINT21 and absorption, 
Lorentz, and polarization corrections were calculated by SADABS.22 Space group 
determination was carried out by analyzing the Laue symmetry and the systematically 
absent reflections with XPREP.23 Structures were solved by direct or heavy atom methods 
and refinement was performed with the SHELX-97 program suite.24 Refinement was carried 
out against F2 using standard procedures.25 Non-hydrogen atoms were located in difference 
Fourier maps and refined anisotropically. Hydrogen atoms were placed at calculated 
positions and refined using a riding model unless otherwise specified in the corresponding 
CIF (see Electronic Supporting Information, ESI). For coordinated NH3 and terminal CH3 
groups, hydrogen atom isotropic displacement parameters (Uiso) were set equal to 1.5 times 
the Uiso of the atom to which they were attached. For other hydrogen atoms, Uiso = 1.2 Uiso 
of the attached atom. The details of any restraints employed are presented in the 
corresponding CIF (see ESI). All structures were checked for missed higher symmetry and 
twinning with PLATON and were further validated using CheckCIF.26 Least-squares planes 
were fit using XP and visualized using Mercury.24,27 Refinement details are presented in 
Table 1 and depictions of the molecular structures of the platinum complexes from their 
respective crystal structures are shown in Fig. 1.
Computational details
DFT calculations were executed with Gaussian 03.28 The PBE0 hybrid functional was 
employed.29 The valence electrons of the Pt, Br, and I atoms were treated using the 
LANL2DZ basis set and relativistic effects were taken into consideration by employing the 
corresponding LANL2DZ effective core potentials.30,31 The Pople-type 6-31++g(d,p) basis 
set was used for all other atoms.32,33 Geometry optimizations were carried out for 4, 5, and 
6 in the gas phase followed by analytical frequency calculations. The lack of imaginary 
frequencies in the latter was used as confirmation that the converged-upon geometry is 
indeed a minimum on the potential energy surface of the molecule. Comparison of the 
optimized gas-phase structures to the crystallographically determined molecular structures 
was performed using Mercury.27 Cartesian coordinates for all optimized structures are 
provided in the ESI.
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Results and discussion
Oxidative halogenation of cisplatin
The oxidation of an aqueous suspension of cisplatin with chlorine to form 1 has been 
previously reported,15 as has oxidation of cisplatin with bromine water to afford 2,34 but to 
the best of our knowledge the oxidation of cisplatin using iodine to yield 3 has not been 
described. We report here a general procedure to obtain Pt(IV) trans dihalide complexes by 
treating DMF solutions of the parent platinum(II) compounds with stoichiometric amounts 
of oxidant, followed by precipitation with diethyl ether.
The methods most widely employed in the literature to prepare Pt(IV) prodrugs bearing 
axial chlorides involve oxidation of the Pt(II) precursor with Cl2 or with hydrogen peroxide 
in water to afford the dihydroxide complex followed by treatment with hydrochloric acid.11 
An alternative reaction that in one step both oxidizes and chlorinates the platinum center is 
treatment with PCl5. Phosphorus pentachloride was used to convert [Pt(en)I2] to cis,trans-
[Pt(en)I2Cl2].35 The use of the mono-chlorinating oxidant N-chlorosuccinimide in the 
preparation of prodrugs bearing one axial chloride has very recently been described.36 In 
only a few reports have we and others used iodobenzene dichloride in the preparation of 
platinum anticancer agents bearing axial trans chlorides.11,37-40
Iodobenzene dichloride is readily prepared in a robust reaction using iodobenzene, 
household bleach, and hydrochloric acid.19 Contrary to previous reports of the long term 
instability of this reagent,41-43 we find it to be stable for up to one year if recrystallized from 
chloroform and stored at −40 °C. It can be handled readily in air at room temperature during 
the course of setting up reactions. Moreover, the by-product, iodobenzene, is highly soluble 
in a solvent such as diethyl ether, which is used here to precipitate the desired platinum-
containing products.
When a DMF solution of cisplatin is treated with a DMF solution of iodobenzene dichloride, 
a rapid color change occurs. If the solutions are dilute, the change is marked by a 
brightening of the yellow coloration. If the DMF solutions are at concentrations approaching 
saturation, the reaction mixture initially turns an intense orange, which rapidly converts to 
bright yellow. We have not investigated the details of this reaction, but it is possible that at 
high concentrations a dimeric Pt(III) intermediate may form that is subsequently cleaved.11 
Alternatively, a Pt(IV) intermediate may form in which a solvent molecule is bound trans to 
the initially added chloride. This solvent ligand would then be displaced by the chloride ion 
that is liberated on reduction of the I(III) center in iodobenzene dichloride to I(I). Similar 
solvent-ligated intermediates in the Cl2 oxidation of platinum(II) complexes were 
spectroscopically observed and crystallographically characterized.44-46
Unlike chlorine, bromine and iodine are more readily handled at ambient temperature and 
pressure and so alternative reagents to carry out oxidative bromination and iodination were 
not sought. Oxidation of cisplatin with bromine to form 2 proceeded smoothly as did 
oxidation with iodine to yield 3. Deeply colored, 3 was particularly sensitive to 
photodecomposition when the oxidation was performed without exclusion of light. The 
nature of the decomposition products was not investigated in detail but we note that others 
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have exploited the photoreactivity of Pt(IV) iodide complexes to design photoactivated 
Pt(IV) prodrugs.35,47 A detailed description of the spectroscopic and crystallographic 
properties of 1–3 is presented below.
Oxidative halogenation of carboplatin
The oxidation of carboplatin with iodobenzene dichloride and elemental bromine produced 4 
and 5 in a manner analogous to the corresponding oxidations of cisplatin. We note that, in 
contrast to the iodobenzene dichloride oxidation of cisplatin, no transient red coloration of 
the reaction was observed. If the colored intermediate is a Pt–Pt bonded species, then the 
bulky CBDCA ligand may preclude its formation. A detailed description of the 
spectroscopic and crystallographic properties of 4 and 5 is presented below. Combination of 
a DMF solution of iodine and a suspension of carboplatin initially produced a homogenous 
solution. After a few minutes, a yellow solid appeared in the reaction mixture and addition 
of diethyl ether induced further precipitation of a small amount of yellow microcrystalline 
solid, which was removed by filtration. Further dilution of the filtrate with diethyl ether 
afforded 6 as a dark red-brown solid.
1H NMR spectroscopic analysis of the yellow solid initially formed in the reaction showed, 
in addition to signals corresponding to unreacted carboplatin, the presence of two resonances 
centered at 6.03 and 4.75 ppm, another at 1.83 ppm, and a final one buried under the DMSO 
solvent peak (Fig. S22, ESI). The two most upfield signals exhibit splitting consistent with 
that expected for the resonances of a CBDCA ligand. The remaining two resonances occur 
downfield of where the ammine signals from carboplatin appear, consistent with terminal 
ammines or bridging amides bound to a Pt(IV) center.48,49 The integrated intensities of these 
downfield resonances indicate that they arise from three and two protons, respectively, when 
compared to the integrated intensities of those arising from the cyclobutane fragment of the 
CBDCA ligand. Moreover, the yellow color of the product differed significantly from the 
red or purple hue that would be expected for the desired diiodide compound. X-ray 
crystallographic analysis revealed the species to be the amido-bridged dimer 
[Pt(CBDCA)I(NH3)(μ-NH2)]2, which is consistent with these 1H NMR spectral data. A 
detailed description of the structure of this species is presented below.
NMR spectroscopic trends
Spectroscopic investigation of the compounds reported here not only provides a means of 
confirming their identities but also reveals trends as the halide ligands are varied. The 1H 
NMR spectral signals of the NH3 ligands of 1–6 show a characteristic splitting pattern 
induced by coupling to both 195Pt (I = ½) and quadrupolar 14N (I = 1). Whereas 14N exhibits 
99.6% natural abundance, 195Pt is only 33.8% abundant. Two-bond coupling of the ammine 
protons to the 195Pt nucleus produces additional satellite peaks. Resolution of these coupling 
effects is often complicated by broadening from quadrupolar relaxation of 14N and chemical 
shift anisotropy (CSA) of 195Pt. The former is greatly reduced upon oxidation of Pt(II) to 
Pt(IV) because of symmetrization of the electric field gradient at the 14N nucleus.39 The 
CSA of the platinum nucleus is also greatly reduced on transitioning from square-planar 
Pt(II) to octahedral Pt(IV).50 The combination of these two effects allows coupling to be 
readily observed. Coupling of 1H to both 14N and 195Pt is expected to produce 1:1:1 triplet, 
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each component of which will bear satellite peaks. The coupling constants of the two 
interactions happen to be approximately equal, which positions the satellite peaks of the 
inner member of the 1:1:1 triplet directly over those of the outer members of the triplet. The 
pattern experimentally observed for 2 is shown in Fig. 2. Variation of the axial halide 
ligands induces a systematic shift in the resonant absorption of the ammine protons. The 
upfield shift in the resonances from 1 (5.87 pm) to 2 (5.84 ppm) to 3 (5.77 ppm) is 
consistent with greater shielding conveyed by the less electronegative halides.
As stated above, oxidation to Pt(IV) symmetrizes the electric field gradient of the 14N 
nucleus, which permits direct observation of sharp 14N NMR signals for 1 and 2.39 Fully 
coupled spectra could be obtained (Fig. S3), but proton-decoupling (Fig. S4 and S9) 
enhanced the signal-to-noise ratio and allowed platinum satellites to be clearly observed for 
both 1 and 2. As observed for the 1H NMR signals, the 14N resonances shift upfield with 
change of the axial halide ligand from chloride to bromide, from −33.7 ppm to −40.9 ppm. 
The 1J(14N–195Pt) coupling constants do not vary significantly between 1 and 2, which 
exhibit values of 177 Hz and 175 Hz, respectively. The magnitude of this coupling is related 
to hybridization at the platinum center and the nature of the ligand trans to the ammine.51 
The variation of less than 1.5% in the 1J(14N–195Pt) values of 1 and 2 is consistent with the 
lack of Pt rehybridization and the congruence of the ligand trans to the ammine.
195Pt NMR spectroscopy provides a highly sensitive measure of coordination environment 
and oxidation state, and platinum complexes exhibit a chemical shift range of approximately 
13000 ppm.52 The significant downfield shift observed following treatment of cisplatin (δ ≈ 
−2100)50 with iodobenzene dichloride, bromine, or iodine is consistent with oxidation of the 
Pt(II) center to the 4+ state.53 As with the 1H and 14N spectroscopic experiments described 
above, the 195Pt resonances shift with the halide ligands as follows: −123 ppm for 1, −732 
ppm for 2, and −1866 ppm for 3. In the theory developed by Ramsey and elaborated by 
others,54 chemical shift is divided into a diamagnetic part and a paramagnetic part. 
Paramagnetic shielding is the dominant interaction in dictating changes to the chemical shift 
of the 195Pt nucleus as a function of changing ligand field.55 The degree of paramagnetic 
shielding afforded to a transition metal by its ligands follows the same trend as the position 
of those ligands in the nephelauxetic series;56 the 195Pt chemical shifts of 1–3 vary 
accordingly. More recent revisions of this theory have recognized the important contribution 
of spin-orbit coupling to the 195Pt chemical shift.57 The nephelauxetic series trend described 
above is a manifestation of this spin-orbit coupling effect, which increases as Cl < Br < I.57
The splitting pattern of the 195Pt NMR signal expected from coupling to the two 
equivalent 14N nuclei and the six equivalent protons is a pentet of septets. In general, efforts 
were not taken to resolve these couplings, but careful measurement and processing of 
the 195Pt NMR spectrum of 2 permitted their full resolution at 86 MHz (Fig. 2). The 
coupling constants obtained from this spectrum are equivalent to those obtained 
independently from 1H NMR spectra and consistent with those obtained from the 14N NMR 
spectra of 1 and 2. Similar trends were observed in the NMR spectra of the carboplatin 
prodrugs 4–6.
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X-ray crystallographic study of 1 and 3
cis,cis,trans-[Pt(NH3)2Cl2X2], where X = Cl or I, both crystallize from DMF with the same 
structural motif in which each platinum complex crystallizes with three DMF molecules. 
The ability this solvent to yield large crystals of cis-[Pt(NH3)2Cl2]·DMF has been exploited 
as a means of purifying cisplatin.58,59 The carbonyl fragments of the DMF molecules act as 
hydrogen bond acceptors for the platinum-bound ammine ligands. Hydrogen bonding 
metrics, determined using PLATON, are reported in the ESI (Tables S9–S18). In the 
structures of 1 and 3, the oxygen atom of one DMF forms hydrogen bonds with the two cis 
ammines of one platinum complex. The remaining two solvent molecules bridge symmetry-
related platinum complexes. In the structure of 1·3DMF, these bridging DMF molecules 
form hydrogen-bonded chains that propagate along the b axis (Fig. 3). In the structure of 
3·3DMF, there are two symmetry-independent platinum complexes within the asymmetric 
unit. Each has three DMF molecules associated with it and forms a hydrogen-bonding 
network similar to that described above. In both cases, the hydrogen bonded chains 
propagate along b. One set of chains has close I···I contacts (3.6472(6) Å), whereas the other 
does not and its closest I···I distance is 4.4321(7) Å (Fig. 3). Crystal structures containing 
more than one crystallographically independent molecule in the asymmetric unit can arise 
from frustration between different types of intermolecular interactions.60 In this structure, 
such competition may be occurring between hydrogen bonding and the iodide–iodide 
interaction.
The cisplatin prodrugs 1 and 3 both have a pseudo-octahedral coordination geometry in 
which the core structure of the cis-diamminedichloroplatinum unit is maintained. The 
equatorial Pt–N and Pt–Cl bond lengths do not vary significantly from those in the structure 
of cisplatin.61 The axial ligands form an X–Pt–X angle of 174.24(2)° for X = Cl (1) and 
176.91(1)° and 179.06(1)° for the two crystallographically independent molecules of 3, for 
which X = I. In each case, the axial ligands bend away from the equatorial chlorides toward 
the ammine ligands. The greater steric bulk of the equatorial chloride ligands compared to 
the ammines pushes the axial halides in this direction. As the length of the Pt–X bond of the 
axial ligands increases, this steric strain decreases and the X–Pt–X angle approaches 180°.
During the selection of a suitable sample of 1 for X-ray diffraction analysis, one single 
crystal of all those investigated microscopically had a slightly different color. Instead of the 
bright yellow characteristic of 1·3DMF, it had a tint of orange, which was particularly 
evident when viewed under crossed polarizers. Diffraction analysis revealed this crystal to 
contain fac-[Pt(NH3)3Cl3]Cl·DMF, which appears to have formed by decomposition during 
the extended crystallization time. A detailed analysis of the structure of this compound is not 
provided here but refinement details, a thermal ellipsoid plot, and the CIF are provided as 
ESI. We briefly note that it is only the fourth platinum compound to be deposited in the 
CSD containing a facial arrangement of three chloride and three N-donor ligands.62-64 The 
crystal structure of fac-[Pt(NH3)3Br3]Br·DMF was also obtained but is not discussed further 
(details in ESI). No other platinum compound with a facial coordination of three bromide 
and three N-donor ligands has been deposited in the CSD.
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X-ray crystallographic study of 4 and 5
Crystal structures of the carboplatin prodrugs 4 and 5 were also solved. The crystals were 
obtained from DMF and, as with the cisplatin prodrugs described above, the two share 
common structural motifs. The carboplatin prodrugs, unlike the cis-diamminetetrahalo-
platinum(IV) species, have carbonyl fragments from the CBDCA ligand that can serve as 
hydrogen bond acceptors for ammine ligands. The main structural motif is an inversion-
related pair of complexes that form reciprocal hydrogen bonds (Fig. 4). These dimers 
generate chains through hydrogen bonding interactions with DMF. In the structures of both 
4·DMF and 5·DMF, one of the ammine N–H bonds lacks a formal hydrogen bond acceptor, 
but is directed toward the axial halide of an adjacent complex. In the crystals containing 4, 
the N···Cl distance is 3.604(2) Å and the N–H–Cl angle is 173.7°. In the crystals containing 
5, the N···Br distance is 3.817(2) Å and the N–H–Br angle is 168.4°.
The crystal structures also reveal some interesting molecular features. The malonate portion 
of the CBDCA ligand adopts a boat conformation in carboplatin.65 The presence of a single 
set of CBDCA 1H NMR spectral resonances is attributed to rapid flipping of the ligand from 
one boat conformer to the other in solution.66 The conformational dynamics of carboplatin 
have been probed by investigating variable temperature solid state NMR spectra of 
carboplatin derivatives.67 The boat conformation positions the CBDCA ring over one face 
of the platinum complex (Fig. 5), a feature that has been proposed to help protect the 
compound from deactivation by intracellular thiols.68 In compounds 4–6, the steric bulk of 
the axial halide ligands of the Pt(IV) prodrug push the cyclobutane ring away from the face 
of the platinum complex, forcing the malonate chelate ring into a flattened-boat 
conformation (Fig. 5). In the structures described here, five of the atoms are essentially 
coplanar. The flattening of the chelate ring can be quantitated by measuring the dihedral 
angle between the plane that best fits the platinum and ligated oxygen atoms and that which 
best fits the carbonyl and quaternary carbon atoms. These are the blue and red planes, 
respectively, in Fig. 5. The green plane in Fig. 5 is the plane that best fits the platinum-
bound oxygen atoms and the carbonyl carbon atoms. The dihedral angle between the blue 
and red planes is 86° for carboplatin, 41° for 4, and 36° for 5. Although apparently not 
published, a crystal structure of 6 has been deposited in the CSD as a personal 
communication by Sadler and coworkers (CCDC 276866); the corresponding dihedral angle 
in this structure is 30°.
The flattening of the chelate ring appears to stem directly from a steric interaction between 
the halide and the cyclobutane ring and not from any change in the electronic structure of 
the compound induced upon oxidation to the 4+ state. This feature can be appreciated by 
examining the crystal structure of the carboplatin prodrug bearing axial hydroxide ligands, 
cis,trans-[Pt(CBDCA)(NH3)2(OH)2] (details presented in the ESI). In this structure, the 
malonate ring again adopts a flattened-boat conformation but the platinum atom, as opposed 
to the quaternary carbon, is displaced from the plane formed by the other five atoms. This 
difference from the complexes with axial halides most likely arises because of the shorter 
metal-ligand bond and smaller effective radius of the hydroxide ligand. Further 
corroboration of the proposal that these changes in the CBDCA conformation observed in 
these crystal structures arise from intramolecular, as opposed to intermolecular, interactions 
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was provided by computational studies using DFT methods. Geometry optimization in the 
gas phase reproduced the general structural features of carboplatin and complexes 4–6 that 
were determined by X-ray crystallography. These features include the boat conformation of 
the malonate portion of the CBDCA ligand of carboplatin and the flattened-boat 
conformations of the CBDCA ligands of the Pt(IV) prodrugs. The RMSD of the non-H 
atoms of the calculated and experimental structures for 4, 5, and 6 are 0.12 Å, 0.13 Å, and 
0.26 Å, respectively. These computed structures of 4–6 support the hypothesis that, as the 
radius of the halide ligand increases, the malonate ring of the CBDCA ligand is pushed 
toward a planar conformation.
Crystal structure of 7·3DMF·Et2O
There are examples of amido-bridged complexes of platinum(II),69-72 platinum(III),39,73 and 
platinum(IV)48,49 that have been characterized spectroscopically and crystallographically. In 
these systems, crystallographic characterization often requires careful consideration. For 
instance, reanalysis of the structure of a head-to-tail tetranuclear Pt(III) complex initially 
formulated74 as [(H2O)(H3N)2Pt(μ-C4H6NO)2Pt(NH3)(μ-OH2)]2 revealed that the bridging 
hydroxide ligands are most likely bridging amide ligands.39 Analysis of the hydrogen 
bonding patterns in the crystal structure of 7·3DMF·Et2O confirms that the bridging ligands 
are amides in both crystallographically independent dimers. The calculated Z value of 2 
suggested one dimer in the asymmetric unit centered on a general position. Solution of the 
structure revealed instead the presence of two crystallographically independent half-dimers 
on different inversion centers. A parameter typically used to describe the number of 
independent molecules within the asymmetric unit is Z′,75 defined as the number of formula 
units in the unit cell divided by the multiplicity of a general position in the space group. This 
definition, however, does not account for cases in which molecules sit on 
crystallographically distinct special positions. In the case of the structure of 7·3DMF·Et2O, 
Z′ = 1, but the crystal clearly contains two crystallographically independent molecules. In 
the extended Z′ descriptor notation, developed to handle cases of this sort, this structure 
would be described as having Z′ = ½ + ½. In the notation developed by Zorkii and Bel’skii, 
the structure class symbol for this crystal structure is P, Z = 2(,), where the numbers in 
parentheses represent the site-symmetries of the distinct special position upon which the 
crystallographically independent molecules sit.76 An analysis of the structures deposited in 
the CSD revealed the relative occurrence of crystal structures in which molecules sit upon 
distinct special positions.77 Although this phenomenon is rare, the case in which the 
molecule crystallizes in space group P with two molecules sitting on different inversion 
centers is its most common manifestation.77
Care must be taken to ensure that a shift of the origin or reduction of unit cell size will not 
reveal these two half molecules to be crystallographically related. In the present structure, 
the two molecules engage in distinct hydrogen bonding patterns. In one dimer, the two 
hydrogen atoms of the bridging amide are directed toward the carbonyl moieties of DMF 
molecules. In the other, one amide hydrogen atom is directed toward a DMF carbonyl and 
the other is directed toward the carbonyl of the CBDCA ligand from a neighboring complex. 
Moreover, the cyclobutane ring of one of the half-dimers in the asymmetric unit is 
disordered across the two pucker conformations, whereas the other is well ordered. With the 
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exception of a differential puckering of the cyclobutane ring, the structures of the two 
crystallographically independent dimers are essentially identical. Because one of the Pt–N 
bonds of the bridging amide is trans to a strongly trans-directing iodide ligand and the other 
is trans to a carboxylate, the Pt2N2 rhomb is not equilateral. For the two crystallographically 
independent molecules, the length of the Pt–N bond trans to the iodide is 2.066(5)/2.058(3) 
Å and that of the bond trans to carboxylate is 2.028(3)/2.020(3) Å. As expected, the 
platinum atoms are sufficiently far apart, 3.1100(3)/3.0910(4) Å, that there is no covalent 
interaction between them.
Conclusions
The Pt(IV) prodrug approach holds significant promise for the development of novel 
platinum-based anticancer agents of clinical value. The work described here provides a 
synthetic framework for the facile preparation of prodrugs bearing axial chloride ligands or 
axial halides different from those commonly encountered in the literature. This synthetic 
methodology can be used to obtain complexes intended for direct application to biological 
systems or as synthetic intermediates in the preparation of more complex platinum-
containing molecules. A detailed analysis of the variation in the spectroscopic and structural 
properties induced by altering the axial halide was presented. The ability to systematically 
alter these properties allows chemists to endow a platinum complex with precise attributes 
necessary for a given biological function. The methodologies presented here expand the 
toolkit of synthetic bioinorganic chemists, facilitating such designed syntheses.
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Chart 1. 
Selection of Pt(II) (top) and Pt(IV) complexes (bottom) investigated in a clinical setting.
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Chart 2. 
The target Pt(IV) prodrugs of cisplatin, 1–3, and carboplatin, 4–6.
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Fig. 1. 
Molecular structures of platinum complexes from the crystal structures of a) 1, b) 3, c) 4, d) 
5, and e) 7. Thermal ellipsoids are shown at the 50% probability level and hydrogen atoms 
are shown as spheres of arbitrary radius. Color code: Purple Pt, blue N, red O, grey C, 
magenta I, orange Br. For b) and e) only one of the two crystallographically independent 
molecules present in the asymmetric unit is shown.
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Fig. 2. 
NMR spectra (11.7 T) of 2 showing the coupling between the 1H, 14N, and 195Pt nuclei. 
The 14N spectrum is proton-decoupled to allow the platinum satellites to show more readily. 
Fully annotated spectra are presented in the ESI.
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Fig. 3. 
Crystallographic intermolecular interactions in (a) 1 and (b, c) the two crystallographically 
independent molecules of 3. Hydrogen bonding between the platinum complexes and DMF 
solvent molecules is indicated by dotted blue lines. One of the molecules of 3 also 
participates in close I···I contacts as shown with blue dotted lines in (c). Boxed at the right 
are stereo images of the repeating unit of each motif. Color code: Dark blue Pt, green Cl, 
purple I, light blue N, red O, grey C, white H.
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Fig. 4. 
Intermolecular interactions in the crystal structures of 4 (a) and 5 (b) shown as blue dotted 
lines. Color code: Silver Pt, green Cl, orange Br, blue N, red O, grey C, white H.
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Fig. 5. 
a) Overlay of the crystallographically determined structures of carboplatin (red) and 1 
(blue). b) Planes of best fit indicating the boat conformation of the CBDCA ligand of 
carboplatin. c) Planes of best fit indicating the flattened-boat conformation of the CBDCA 
ligand of 1. The atoms through which the planes are chosen to pass are described in the main 
text.
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Table 1
Crystallographic parameters for 1·3DMF, 3·3DMF, 4·DMF, 5·DMF, and 7·3DMF-Et20
1·3DMF 3·3DMF 4-DMF 5-DMF 7-3DMF-Et20
Formula C9H27C14N5O3Pt C9H27Cl2I2N5O3Pt C9H19C12N3O5Pt C9H19Br2N5O5Pt C22H53I2N7O12Pt2
FW 590.25 773.15 515.26 604.18 1287.72
Space group P21/c P21/c P P 1
‒
P P 1
‒
P P 1
‒
a, Å 10.0850(4) 21.974(3) 8.0456(5) 8.1817(4) 13.0123(11)
b, Å 12.9560(5) 12.4000(14) 10.2110(6) 9.5209(5) 13.2677(11)
c, Å 16.0513(6) 17.573(2) 10.2604(6) 11.4203(5) 13.388(2)
α, ° 98.438(1) 108.009(1) 94.816(2)
β, ° 104.918(1) 112.003(2) 104.454(1) 107.490(1) 100.174(2)
γ, ° 106.933(1) 95.406(1) 118.650(1)
V, Å3 2026.59(14) 4439.6(9) 758.64(8) 789.55(7) 1958.0(4)
Z 4 8 2 2 2
T, K 100(2) 100(2) 100(2) 100(2) 100(2)
μ(Mo Kα), mm−1 7.466 9.358 9.621 13.967 8.775
θ range, ° 2.05 to 28.33 1.92 to 28.97 2.11 to 28.28 2.00 to 28.70 1.58 to 28.37
total data 40197 88414 14758 15848 38217
unique data 5046 11675 3744 4040 9716
parameters 207 413 185 185 453
completeness (%) 99.9 99.3 99.2 99.3 99.2
R1
a
 (%) 1.30 2.63 1.27 1.88 2.27
wR2
b
 (%) 3.01 6.52 3.10 5.12 4.52
GoFc 1.086 1.077 1.064 1.134 1.031
a
R1=Σ∥Fo| - |Fc∥/ Σ|Fo|.
b
wR2= {Σ[w(Fo2-Fc2)2]/Σ[w(Fo2)2]}½.
cGoF= {Σ[w(Fo2-Fc2)2]/(n-p)}1/2
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